Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms.
bradykinins
cancer
microtubule targeting drugs
noscapine
receptors
therapeutics
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
02
08
2021
accepted:
30
08
2021
pubmed:
18
9
2021
medline:
25
2
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
Noscapine has been mentioned as one of the effective drugs with potential therapeutic applications. With few side effects and amazing capabilities, noscapine can be considered different from other opioids-like structure compounds. Since 1930, extensive studies have been conducted in the field of pharmacological treatments from against malaria to control cough and cancer treatment. Furthermore, recent studies have shown that noscapine and some analogues, like 9-bromonoscapine, amino noscapine, and 9-nitronoscapine, can be used to treat polycystic ovaries syndrome, stroke, and other diseases. Given the numerous results presented in this field and the role of different receptors in the therapeutic effects of noscapine, we aimed to review the properties, therapeutic effects, and the role of receptors in the treatment of noscapine.
Substances chimiques
9-amino-alpha-noscapine
0
9-nitronoscapine
0
Anti-Inflammatory Agents
0
Antimalarials
0
Antineoplastic Agents
0
Antitussive Agents
0
Noscapine
8V32U4AOQU
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
975-991Subventions
Organisme : Mashhad University of Medical Sciences
Informations de copyright
© 2021 International Union of Biochemistry and Molecular Biology.
Références
Chen X, Dang T-TT, Facchini PJ. Noscapine comes of age. Phytochemistry. 2015;111:7-13.
Mahmoudian M, Rahimi-Moghaddam P. The anti-cancer activity of noscapine: a review. Recent Pat Anticancer Drug Discov. 2009;4:92-7.
Tomar R, Sahni A, Chandra I, Tomar V, Chandra R. Review of noscapine and its analogues as potential anti-cancer drugs. Mini Rev Org Chem. 2018;15:345-63.
H. Singh, P. Singh, K. Kumari, A. Chandra, S. K Dass, R. Chandra (2013) A review on noscapine, and its impact on heme metabolism. Curr Drug Metab 14:351-360.
Dang T-TT, Facchini PJ. CYP82Y1 is N-methylcanadine 1-hydroxylase, a key noscapine biosynthetic enzyme in opium poppy. J Biol Chem. 2014;289:2013-26.
P.-J. Robiquet. Ann Chim Phys, (1817), p 275.
Aragón-Poce F, Martı́nez-Fernández E, Márquez-Espinós C, Pérez A, Mora R, Torres LM. History of opium. International Congress Series. 2002;1242:19-21. https://doi.org/10.1016/s0531-5131(02)00600-3
Bernath J. Poppy: the genus Papaver. 1st ed. London: CRC Press; 1999. https://doi.org/10.1201/9780203304181
Chopra R, Knowles R. The action of opium and narcotine in malaria. Indian J Med Res. 1930;18(1):5-13.
Winzer T, Gazda V, He Z, Kaminski F, Kern M, Larson TR, et al. A Papaver somniferum 10-gene cluster for synthesis of the anticancer alkaloid noscapine. Science. 2012;336:1704-8.
Matthiessen A, Foster G. XLII.-researches into the chemical constitution of narcotine, and of its products of decomposition.-part I. J Chem Soc. 1863;16:342-64.
Rida PC, LiVecche D, Ogden A, Zhou J, Aneja R. The noscapine chronicle: a pharmaco-historic biography of the opiate alkaloid family and its clinical applications. Med Res Rev. 2015;35:1072-96.
Tomar V, Kukreti S, Prakash S, Madan J, Chandra R. Noscapine and its analogs as chemotherapeutic agent: current updates. Curr Top Med Chem. 2017;17:174-88.
Shono T, Hamaguchi H, Sasaki M, Fujita S, Nagami K. Novel zinc-promoted alkylation of iminium salts. New synthesis of benzylisoquinoline, phthalidylisoquinoline, and protoberberine alkaloids and related compounds. J Org Chem. 1983;48:1621-8.
Kametani T, Ujiie A, Huang S-P, Ihara M, Fukumoto K. Studies on the syntheses of heterocyclic compounds. Part 683. Stevens rearrangement of berbine methiodides by sodium bis-(2-methoxyethoxy) aluminium hydride. J Chem Soc Perkin Trans. 1977;1:394-7.
Allen AC, Cooper DA, Moore JM, Gloger M, Neumann H. Illicit heroin manufacturing by-products: capillary gas chromatographic determination and structural elucidation of narcotine-and norlaudanosine-related compounds. Anal Chem. 1984;56:2940-7.
Gaál G, Kerekes P, Bognár R. Über die Begleitalkaloide des Morphins, VI Die Darstellung der Narcotin-Isomeren. J Prakt Chem. 1971;313:935-9.
Altinoz MA, Topcu G, Hacimuftuoglu A, Ozpinar A, Ozpinar A, Hacker E, et al. Noscapine, a non-addictive opioid and microtubule-inhibitor in potential treatment of glioblastoma. Neurochem Res. 2019;44(8):1796-1806.
Robinson R. LXXV.-a theory of the mechanism of the phytochemical synthesis of certain alkaloids. J Chem Soc Trans. 1917;111:876-99.
Maria Del Pilar CS, Shankaraiah N, Santos LS. Short synthesis of noscapine, bicuculline, egenine, capnoidine, and corytensine alkaloids through the addition of 1-siloxy-isobenzofurans to imines. Tetrahedron Lett. 2010;51:1770-3.
Madan J, Pandey RS, Jain UK, Katare OP, Aneja R, Katyal A. Sterically stabilized gelatin microassemblies of noscapine enhance cytotoxicity, apoptosis and drug delivery in lung cancer cells. Colloids Surf B Biointerfaces. 2013;107:235-44.
Pannu V, Rida P, Ogden A, Clewley R, Cheng A, Karna P, et al. Induction of robust de novo centrosome amplification, high-grade spindle multipolarity and metaphase catastrophe: a novel chemotherapeutic approach. Cell Death Dis. 2012;3:e346.
Karna P, Zughaier S, Pannu V, Simmons R, Narayan S, Aneja R. Induction of reactive oxygen species-mediated autophagy by a novel microtubule-modulating agent. J Biol Chem. 2010;285:18737-48.
Madan J, Gundala SR, Baruah B, Nagaraju M, Yates C, Turner T, et al. Cyclodextrin complexes of reduced bromonoscapine in guar gum microspheres enhance colonic drug delivery. Mol Pharm. 2014;11:4339-49.
Naik PK, Santoshi S, Rai A, Joshi HC. Molecular modelling and competition binding study of Br-noscapine and colchicine provide insight into noscapinoid-tubulin binding site. J Mol Graph Model. 2011;29:947-55.
Zughaier S, Karna P, Stephens D, Aneja R. Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs. PLoS One. 2010;5:e9165.
Zhou J, Gupta K, Aggarwal S, Aneja R, Chandra R, Panda D, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol. 2003;63:799-807.
Debono AJ, Mistry SJ, Xie J, Muthiah D, Phillips J, Ventura S, et al. The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents. ChemMedChem. 2014;9:399-410.
Verma AK, Bansal S, Singh J, Tiwari RK, Sankar VK, Tandon V, et al. Synthesis and in vitro cytotoxicity of haloderivatives of noscapine. Bioorg Med Chem. 2006;14:6733-6.
Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Gupta MV, et al. A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer. 2010;46:1668-78.
Pannu V, Karna P, Sajja HK, Shukla D, Aneja R. Synergistic antimicrotubule therapy for prostate cancer. Biochem Pharmacol. 2011;81:478-87.
Madan J, Baruah B, Nagaraju M, Abdalla MO, Yates C, Turner T, et al. Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm. 2012;9:1470-80.
Jyoti K, Kaur K, Pandey RS, Jain UK, Chandra R, Madan J. Inhalable nanostructured lipid particles of 9-bromo-noscapine, a tubulin-binding cytotoxic agent: in vitro and in vivo studies. J Colloid Interface Sci. 2015;445:219-30.
Aneja R, Vangapandu SN, Lopus M, Chandra R, Panda D, Joshi HC. Development of a novel nitro-derivative of noscapine for the potential treatment of drug-resistant ovarian cancer and T-cell lymphoma. Mol Pharmacol. 2006;69:1801-9.
Santoshi S, Naik PK. Molecular insight of isotypes specific β-tubulin interaction of tubulin heterodimer with noscapinoids. J Comput Aided Mol Des. 2014;28:751-63.
Naik PK, Chatterji BP, Vangapandu SN, Aneja R, Chandra R, Kanteveri S, et al. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid. J Comput Aided Mol Des. 2011;25:443-54.
DeBono AJ, Xie JH, Ventura S, Pouton CW, Capuano B, Scammells PJ. Synthesis and biological evaluation of N-substituted noscapine analogues. ChemMedChem. 2012;7:2122-33.
Manchukonda NK, Naik PK, Sridhar B, Kantevari S. Synthesis and biological evaluation of novel biaryl type α-noscapine congeners. Bioorg Med Chem Lett. 2014;24:5752-7.
Manchukonda NK, Naik PK, Santoshi S, Lopus M, Joseph S, Sridhar B, et al. Rational design, synthesis, and biological evaluation of third generation α-noscapine analogues as potent tubulin binding anti-cancer agents. PLoS One. 2013;8:e77970.
Santoshi S, Manchukonda NK, Suri C, Sharma M, Sridhar B, Joseph S, et al. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents. J Comput Aided Mol Des. 2015;29:249-70.
Karlsson MO, Dahlström B, Eckernäs SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. Eur J Clin Pharmacol. 1990;39:275-9.
Andey T, Patel A, Marepally S, Chougule M, Spencer SD, Rishi AK, et al. Formulation, pharmacokinetic, and efficacy studies of mannosylated self-emulsifying solid dispersions of noscapine. PLoS One. 2016;11:e0146804.
Madan J, Dhiman N, Sardana S, Aneja R, Chandra R, Katyal A. Long-circulating poly (ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anti-Cancer Drugs. 2011;22:543-55.
Sweetman S. Cough suppressants, expectorants, mucolytics and nasal decongestants. Martindale-the complete drug reference. 33rd ed. London, UK: Pharmaceutical Press; 2002. p. 1082-102.
Dahlström B, Mellstrand T, Löfdahl C-G, Johansson M. Pharmakokinetic properties of noscapine. Eur J Clin Pharmacol. 1982;22:535-9.
Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, et al. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol. 2007;60:831-9.
Ohlsson S, Holm L, Myrberg O, Sundström A, Yue Q-Y. Noscapine may increase the effect of warfarin. Br J Clin Pharmacol. 2008;65:277-8.
Lasagna L, Owens A Jr, Shnider B, Gold G. Toxicity after large doses of noscapine. Cancer Chemother Rep. 1961;15:33-4.
Zhang N, Seguin RP, Kunze KL, Zhang Y-Y, Jeong H. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy. Drug Metab Dispos. 2013;41:2114-23.
Su W, Huang L, Ao Q, Zhang Q, Tian X, Fang Y, et al. Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1α. Cancer Lett. 2011;305:94-9.
Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, et al. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem. 2002;277:39777-85.
Mooraki A, Jenabi A, Jabbari M, Zolfaghari MI, Javanmardi SZ, Mahmoudian M, et al. Noscapine suppresses angiotensin converting enzyme inhibitors-induced cough. Nephrology (Carlton). 2005;10:348-50.
Ebrahimi SA, Zareie MR, Rostami P, Mahmoudian M. Interaction of noscapine with the bradykinin mediation of the cough response. Acta Physiol Hung. 2003;90:147-55.
Tripathi M, Reddy P, Rawat D. Noscapine and its analogues as anti-cancer agents. Chem Biol Interface. 2014;4:240.
Karlsson MO, Dahlström B, Neil A. Characterization of high-affinity binding sites for the antitussive [3H] noscapine in Guinea pig brain tissue. Eur J Pharmacol. 1988;145:195-203.
Kamei J, Iwamoto Y, Misawa M, Kasuya Y. Effects of rimcazole, a specific antagonist of σ sites, on the antitussive effects of non-narcotic antitussive drugs. Eur J Pharmacol. 1993;242:209-11.
Ye K, Ke Y, Keshava N, Shanks J, Kapp JA, Tekmal RR, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA. 1998;95:1601-6.
Zhou J, Panda D, Landen JW, Wilson L, Joshi HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem. 2002;277:17200-8.
Tomaszek S, Wigle DA, Keshavjee S, Fischer S. Thymomas: review of current clinical practice. Ann Thorac Surg. 2009;87:1973-80.
Tormoehlen LM, Pascuzzi RM. Thymoma, myasthenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am. 2008;22:509-26.
Barken I, Geller J, Rogosnitzky M. Noscapine inhibits human prostate cancer progression and metastasis in a mouse model. Anticancer Res. 2008;28:3701-4.
Mahmoudian M, Aboutaleb N, Beiranvand F, Moazzam A-A, Shafiei M. Noscapine antagonizes vasoconstrictor action of bradykinin in isolated human umbilical artery. Med J Islam Repub Iran. 2011;25:82-6.
Mahmoudian M, Mojaverian N. Effect of noscapine, the antitussive opioid alkaloid, on bradykinin-induced smooth muscle contraction in the isolated ileum of the Guinea-pig. Acta Physiol Hung. 2001;88:231-7.
Kamikawa Y, Shimo Y. Inhibitory effects of non-narcotic antitussive drugs on cholinergically and non-cholinergically mediated neurogenic contractions of Guinea-pig isolated bronchial muscle. J Pharm Pharmacol. 1991;43:242-6.
Coulter D, Edwards I. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed). 1987;294:1521-3.
Kotzer CJ, Hay DW, Dondio G, Giardina G, Petrillo P, Underwood DC. The antitussive activity of δ-opioid receptor stimulation in Guinea pigs. J Pharmacol Exp Ther. 2000;292:803-9.
Ebrahimi SA. Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2. Drug Dev Res. 2020;81:765-7.
Kumar D, Kumari K, Jayaraj A, Kumar V, Kumar RV, Dass SK, et al. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures. J Biomol Struct Dyn. 2020;39:2659-72. https://doi.org/10.1080/07391102.2020.1752310
Kumar N, Sood D, van der Spek PJ, Sharma HS, Chandra R. Molecular binding mechanism and pharmacology comparative analysis of Noscapine for repurposing against SARS-CoV-2 protease. J Proteome Res. 2020;19:4678-89.
Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, et al. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release. 2011;149:314-22.
Greene EL, Velarde V, Jaffa AA. Role of reactive oxygen species in bradykinin-induced mitogen-activated protein kinase and c-fos induction in vascular cells. Hypertension. 2000;35:942-7.
Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611-21.
Mahmoudian M, Mehrpour M, Benaissa F, Siadatpour Z. A preliminary report on the application of noscapine in the treatment of stroke. Eur J Clin Pharmacol. 2003;59:579-81.
Kawadkar M, Mandloi AS, Saxena V, Tamadaddi C, Sahi C, Dhote VV. Noscapine alleviates cerebral damage in ischemia-reperfusion injury in rats. Naunyn Schmiedeberg's Arch Pharmacol. 2020;394(4):669-83.
Dey I, Lejeune M, Chadee K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br J Pharmacol. 2006;149:611-23.
Nielsen M, Fleet I, Jakobsen K, Heap R. The local differential effect of prostacyclin, prostaglandin E2 and prostaglandin F2α on mammary blood flow of lactating goats. J Endocrinol. 1995;145:585-91.
Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986-1000.
North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447:1007-11.
Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108:15-23.
Lacy SH, Woeller CF, Thatcher TH, Pollock SJ, Small EM, Sime PJ, et al. Activated human lung fibroblasts produce extracellular vesicles with antifibrotic prostaglandins. Am J Respir Cell Mol Biol. 2019;60:269-78.
Palayoor S, Youmell M, Calderwood S, Coleman C, Price B. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene. 1999;18:7389-94.
Netea MG, Van der Meer JW, Kullberg B-J. Toll-like receptors as an escape mechanism from the host defense. Trends Microbiol. 2004;12:484-8.
Underhill DM. Mini-review toll-like receptors: networking for success. Eur J Immunol. 2003;33:1767-75.
Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6:823-35.
Newcomb EW, Lukyanov Y, Schnee T, Ali MA, Lan L, Zagzag D. Noscapine inhibits hypoxia-mediated HIF-1α expression andangiogenesis in vitro: a novel function for an old drug. Int J Oncol. 2006;28:1121-30.
Sung B, Ahn KS, Aggarwal BB. Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-κB signaling pathway. Cancer Res. 2010;70:3259-68.
Ye K, Zhou J, Landen JW, Bradbury EM, Joshi HC. Sustained activation of p34 cdc2 is required for noscapine-induced apoptosis. J Biol Chem. 2001;276:46697-700.
Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. Int J Mol Sci. 2020;21:2346.
Heasley LE, Han S-Y. JNK regulation of oncogenesis. Mol Cells. 2006;21(2):167-73.
Yang D, Tournier C, Wysk M, Lu H-T, Xu J, Davis RJ, et al. Targeted disruption of the MKK4 gene causes embryonic death, inhibition of c-Jun NH2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA. 1997;94:3004-9.
Ogden A, Cheng A, Rida P, Pannu V, Osan R, Clewley R, et al. Quantitative multi-parametric evaluation of centrosome declustering drugs: centrosome amplification, mitotic phenotype, cell cycle and death. Cell Death Dis. 2014;5:e1204.
Lopus M, Naik PK. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics. Pharmacol Rep. 2015;67:56-62.
DeBono A, Capuano B, Scammells PJ. Progress toward the development of noscapine and derivatives as anticancer agents. J Med Chem. 2015;58:5699-727.
Alisaraie L, Tuszynski JA. Determination of noscapine's localization and interaction with the tubulin-α/β heterodimer. Chem Biol Drug Des. 2011;78:535-46.
Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother. 2000;49:217-25.
Nuñez G, Benedict MA, Hu Y, Inohara N. Caspases: the proteases of the apoptotic pathway. Oncogene. 1998;17:3237-45.
Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4:721-9.
Lorenz M, Vollmer B, Unsay JD, Klupp BG, García-Sáez AJ, Mettenleiter TC, et al. A single herpesvirus protein can mediate vesicle formation in the nuclear envelope. J Biol Chem. 2015;290:6962-74.
Orlando KA, Stone NL, Pittman RN. Rho kinase regulates fragmentation and phagocytosis of apoptotic cells. Exp Cell Res. 2006;312:5-15.
O'Brien MA, Kirby R. Apoptosis: a review of pro-apoptotic and anti-apoptotic pathways and dysregulation in disease. J Vet Emerg Crit Care. 2008;18:572-85.
Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res. 2010;316:887-99.
Shen W, Liang B, Yin J, Li X, Cheng J. Noscapine increases the sensitivity of drug-resistant ovarian cancer cell line SKOV3/DDP to cisplatin by regulating cell cycle and activating apoptotic pathways. Cell Biochem Biophys. 2015;72:203-13.
Delgado-López P, Corrales-García E. Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol. 2016;18:1062-71.
Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, et al. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014;23:1985-96.
Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly (ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine. 2013;9:492-503.
Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Res. 2004;10:5187-201.
Altinoz MA, Bilir A, Del Maestro RF, Tuna S, Ozcan E, Gedikoglu G. Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro. Surg Neurol. 2006;65:478-84.
Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, et al. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett. 2011;312:245-52.
Qi Q, Liu X, Li S, Joshi HC, Ye K. Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin. 2013;34:930-8.
Erguven M, Bilir A, Yazihan N, Ermis E, Sabanci A, Aktas E, et al. Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine. Cancer Cell Int. 2011;11:1-11.
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321:288-300.
Chougule MB, Patel AR, Jackson T, Singh M. Antitumor activity of Noscapine in combination with doxorubicin in triple negative breast cancer. PLoS One. 2011;6:e17733.
Madan J, Gundala SR, Kasetti Y, Bharatam PV, Aneja R, Katyal A, et al. Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy. Anti-Cancer Drugs. 2014;25:704-16.
Aneja R, Ghaleb AM, Zhou J, Yang VW, Joshi HC. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res. 2007;67:3862-70.
Yang Z-R, Liu M, Peng X-L, Lei X-F, Zhang J-X, Dong W-G. Noscapine induces mitochondria-mediated apoptosis in human colon cancer cells in vivo and in vitro. Biochem Biophys Res Commun. 2012;421:627-33.
Liu M, Luo X-J, Liao F, Lei X-F, Dong W-G. Noscapine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Cancer Chemother Pharmacol. 2011;67:605-12.
Jackson T, Chougule MB, Ichite N, Patlolla RR, Singh M. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. Cancer Chemother Pharmacol. 2008;63:117-26.
Chougule M, Patel AR, Sachdeva P, Jackson T, Singh M. Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. Lung Cancer. 2011;71:271-82.